RxDoctor Payments Data

Donna Dillard, MD

Family Medicine · Dandridge, TNNPI 1801819198

Payments from drug & device makers

$8,880in general payments, 2019–2025

Across 592 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$1K
  • AbbVie$985
  • Pfizer$742
  • AstraZeneca$653
  • Boehringer Ingelheim$576
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$8,859100%
  • Education$80%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,880 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$156,140
Medicare patients
228
Services billed
8,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$142,727
Tresiba Flextouch U-200Insulin Degludec31$68,126
MounjaroTirzepatide45$62,936
TrulicityDulaglutide40$61,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$61,400
JardianceEmpagliflozin53$55,828
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$38,609
GlatopaGlatiramer Acetate14$34,440
OzempicSemaglutide23$34,195
MyrbetriqMirabegron48$33,230
LinzessLinaclotide20$24,075
RybelsusSemaglutide18$19,139
Tresiba Flextouch U-100Insulin Degludec15$18,266
GlyxambiEmpagliflozin/Linagliptin17$14,112
XareltoRivaroxaban15$12,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$742$142,727137 claims
Lilly USA, LLCMounjaro, Trulicity$172$124,86185 claims
Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat$576$80,05384 claims
GSKTrelegy Ellipta$1,435$61,40071 claims
Novo NordiskOzempic, Rybelsus$1,232$53,33441 claims
Astellas Pharma US IncMyrbetriq$51$33,23048 claims
AbbVieLinzess$985$24,07520 claims
AstraZenecaFarxiga, Brilinta$653$15,22623 claims
Johnson & JohnsonXarelto$202$12,26015 claims
MerckJanuvia$43$5,89811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Dandridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →